Recruitment and Baseline Characteristics of Participants in the AgeWell.de Study-A Pragmatic Cluster-Randomized Controlled Lifestyle Trial against Cognitive Decline.

AgeWell.de RCT cluster-randomized controlled trial cognitive function dementia general practitioner intervention lifestyle prevention primary care trial

Journal

International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455

Informations de publication

Date de publication:
07 01 2021
Historique:
received: 25 11 2020
revised: 02 01 2021
accepted: 05 01 2021
entrez: 12 1 2021
pubmed: 13 1 2021
medline: 15 1 2021
Statut: epublish

Résumé

Targeting dementia prevention, first trials addressing multiple modifiable risk factors showed promising results in at-risk populations. In Germany, AgeWell.de is the first large-scale initiative investigating the effectiveness of a multi-component lifestyle intervention against cognitive decline. We aimed to investigate the recruitment process and baseline characteristics of the AgeWell.de participants to gain an understanding of the at-risk population and who engages in the intervention. General practitioners across five study sites recruited participants (aged 60-77 years, Cardiovascular Risk Factors, Aging, and Incidence of Dementia/CAIDE dementia risk score ≥ 9). Structured face-to-face interviews were conducted with eligible participants, including neuropsychological assessments. We analyzed group differences between (1) eligible vs. non-eligible participants, (2) participants vs. non-participants, and (3) between intervention groups. Of 1176 eligible participants, 146 (12.5%) dropped out before baseline; the study population was thus 1030 individuals. Non-participants did not differ from participants in key sociodemographic factors and dementia risk. Study participants were M = 69.0 (SD = 4.9) years old, and 52.1% were women. The average Montreal Cognitive Assessment/MoCA score was 24.5 (SD = 3.1), indicating a rather mildly cognitively impaired study population; however, 39.4% scored ≥ 26, thus being cognitively unimpaired. The bandwidth of cognitive states bears the interesting potential for differential trial outcome analyses. However, trial conduction is impacted by the COVID-19 pandemic, requiring adjustments to the study protocol with yet unclear methodological consequences.

Identifiants

pubmed: 33430189
pii: ijerph18020408
doi: 10.3390/ijerph18020408
pmc: PMC7825589
pii:
doi:

Types de publication

Journal Article Multicenter Study Pragmatic Clinical Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : German Federal Ministry for Education and Research (BMBF)
ID : 01GL1704A, 01GL1704B, 01GL1704C, 01GL1704D, 01GL1704E, 01GL1704F
Pays : International

Références

J Affect Disord. 2018 Jan 15;226:28-35
pubmed: 28942203
Lancet. 2015 Jun 6;385(9984):2255-63
pubmed: 25771249
Br J Psychiatry. 1973 Oct;123(575):467-70
pubmed: 4748864
Alzheimer Dis Assoc Disord. 2009 Jul-Sep;23(3):198-204
pubmed: 19812459
Alzheimers Dement. 2020 Jul;16(7):1078-1094
pubmed: 32627328
J Affect Disord. 2007 Apr;99(1-3):203-11
pubmed: 17055064
Front Psychiatry. 2020 May 04;11:330
pubmed: 32431627
Lancet. 2020 Aug 8;396(10248):413-446
pubmed: 32738937
Int J Environ Res Public Health. 2014 Sep 10;11(9):9345-60
pubmed: 25211775
Neuroepidemiology. 2013;41(1):35-41
pubmed: 23712106
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013 May;56(5-6):786-94
pubmed: 23703499
Lancet Neurol. 2017 May;16(5):377-389
pubmed: 28359749
J Child Psychol Psychiatry. 2001 Feb;42(2):241-51
pubmed: 11280420
Nutr J. 2010 Sep 14;9:36
pubmed: 20840739
Gerontologist. 2006 Aug;46(4):503-13
pubmed: 16921004
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013 May;56(5-6):802-8
pubmed: 23703501
BMC Geriatr. 2019 Aug 1;19(1):203
pubmed: 31370792
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013 May;56(5-6):650-5
pubmed: 23703482
J Gerontol B Psychol Sci Soc Sci. 2018 Apr 16;73(suppl_1):S20-S28
pubmed: 29669097
Arch Neurol. 2007 Sep;64(9):1323-9
pubmed: 17846273
Md State Med J. 1965 Feb;14:61-5
pubmed: 14258950
Neurology. 1989 Sep;39(9):1159-65
pubmed: 2771064
J Alzheimers Dis. 2018;64(1):71-78
pubmed: 29865075
Neurology. 2020 Aug 4;95(5):e519-e531
pubmed: 32611641
Nervenarzt. 2001 Mar;72(3):196-203
pubmed: 11268764
Psychopharmacol Bull. 1988;24(4):641-52
pubmed: 3249766
Clin Epidemiol. 2018 Sep 18;10:1233-1247
pubmed: 30271219
Am J Psychiatry. 1984 Nov;141(11):1356-64
pubmed: 6496779
J Am Geriatr Soc. 2005 Apr;53(4):695-9
pubmed: 15817019
Arch Clin Neuropsychol. 1999 Feb;14(2):167-77
pubmed: 14590600
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013 May;56(5-6):795-801
pubmed: 23703500
J Alzheimers Dis. 2018;64(2):643-655
pubmed: 29945351
Lancet. 2016 Aug 20;388(10046):797-805
pubmed: 27474376
Nat Rev Neurol. 2018 Nov;14(11):653-666
pubmed: 30291317

Auteurs

Susanne Röhr (S)

Institute of Social Medicine, Occupational Health and Public Health (ISAP), Medical Faculty, University of Leipzig, 04103 Leipzig, Germany.
Global Brain Health Institute (GBHI), Trinity College Dublin, D02 PN40 Dublin, Ireland.

Andrea Zülke (A)

Institute of Social Medicine, Occupational Health and Public Health (ISAP), Medical Faculty, University of Leipzig, 04103 Leipzig, Germany.

Melanie Luppa (M)

Institute of Social Medicine, Occupational Health and Public Health (ISAP), Medical Faculty, University of Leipzig, 04103 Leipzig, Germany.

Christian Brettschneider (C)

Department of Health Economics and Health Services Research, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.

Marina Weißenborn (M)

Department of Clinical Pharmacology and Pharmacoepidemiology, University Hospital Heidelberg, 69120 Heidelberg, Germany.

Flora Kühne (F)

Institute of General Practice/Family Medicine, University Hospital of LMU Munich, 80336 Munich, Germany.

Isabel Zöllinger (I)

Institute of General Practice/Family Medicine, University Hospital of LMU Munich, 80336 Munich, Germany.

Franziska-Antonia Zora Samos (FZ)

Institute of General Practice and Family Medicine, Martin-Luther-University Halle-Wittenberg, 06112 Halle (Saale), Germany.

Alexander Bauer (A)

Institute of General Practice and Family Medicine, Martin-Luther-University Halle-Wittenberg, 06112 Halle (Saale), Germany.

Juliane Döhring (J)

Institute of General Practice, University of Kiel, 24105 Kiel, Germany.

Kerstin Krebs-Hein (K)

Institute of General Practice, University of Kiel, 24105 Kiel, Germany.

Anke Oey (A)

Institute for General Practice, Work Group Medical Statistics and IT-Infrastructure, Hannover Medical School, 30625 Hannover, Germany.

David Czock (D)

Department of Clinical Pharmacology and Pharmacoepidemiology, University Hospital Heidelberg, 69120 Heidelberg, Germany.

Thomas Frese (T)

Institute of General Practice and Family Medicine, Martin-Luther-University Halle-Wittenberg, 06112 Halle (Saale), Germany.

Jochen Gensichen (J)

Institute of General Practice/Family Medicine, University Hospital of LMU Munich, 80336 Munich, Germany.

Walter E Haefeli (WE)

Department of Clinical Pharmacology and Pharmacoepidemiology, University Hospital Heidelberg, 69120 Heidelberg, Germany.

Wolfgang Hoffmann (W)

Institute for Community Medicine, University Medicine Greifswald, 17489 Greifswald, Germany.
German Center for Neurodegenerative Diseases (DZNE), Site Rostock/Greifswald, 17489 Greifswald, Germany.

Hanna Kaduszkiewicz (H)

Institute of General Practice, University of Kiel, 24105 Kiel, Germany.

Hans-Helmut König (HH)

Department of Health Economics and Health Services Research, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.

Jochen René Thyrian (JR)

Institute for Community Medicine, University Medicine Greifswald, 17489 Greifswald, Germany.
German Center for Neurodegenerative Diseases (DZNE), Site Rostock/Greifswald, 17489 Greifswald, Germany.

Birgitt Wiese (B)

Institute for General Practice, Work Group Medical Statistics and IT-Infrastructure, Hannover Medical School, 30625 Hannover, Germany.

Steffi G Riedel-Heller (SG)

Institute of Social Medicine, Occupational Health and Public Health (ISAP), Medical Faculty, University of Leipzig, 04103 Leipzig, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH